Pure Encapsulations Ashwagandha 500 mg Review

Generic root extract standardised to 2.5% withanolides — half KSM-66's contracted 5%, with NO patent name on the label. (Corrected 27 Aug 2026: we originally scored this axis on a repeated 5% figure; the Supplement Facts panel says 2.5%.) Pure Encapsulations sources from vetted suppliers with internal lot-to-lot testing, and its QC discipline likely puts it at the top of the generic tier — but 2.5% is the same half-tier as NOW Foods' declared 2.5%, below every 5% patent bottle on both density and verifiability.

Generic standardised extract — does NOT inherit KSM-66's 24+ RCTs or Sensoril's ~11 RCTs by virtue of patent. The trial evidence base for Pure Encapsulations' specific extract is essentially zero: no published placebo-controlled RCTs on this specific bottle's supply chain. The trial data on 'ashwagandha' generically extrapolates somewhat to standardised extracts at similar withanolide percentages, but the evidence-base claim is operationally weaker than for patent-locked bottles. Loses 3 points from KSM-66's 9.5 specifically on the patent-inherited-evidence dimension. The clinical foundation is generic extrapolation, not extract-specific replication.

Pure Encapsulations is the gold standard for consumer-channel QC discipline — practitioner-channel brand (Nestlé Health Science subsidiary) with sourcing audits, lot-to-lot consistency testing, clinical-channel documentation, and hypoallergenic-grade manufacturing protocols. QC documentation runs at the tier above NSF Certified for Sport on the clean-label dimension; QC documentation runs at parallel tier on the heavy-metals/microbial dimension. The 'practitioner-channel' framing isn't marketing — it operationally means the QC is designed for clinicians prescribing to patients with documented sensitivities. Maximum score on the lab-transparency criterion specifically; this is what you're paying for.

The label's serving size is 1 capsule daily. At 2.5% withanolides, that's 12.5 mg withanolides per day — roughly 40% of the ~30 mg active withanolide load in the 600 mg/day Wankhede 2015 / Lopresti 2019 KSM-66 trials this listicle anchors on. That's a real shortfall at the dose the bottle actually directs, not a marginal one. Doubling to 2 capsules (1000 mg/day = 25 mg withanolides) gets closer — still a touch under the trial's active load — but nothing on the label or the brand's own listing ('Take 1 capsule daily, with or between meals') tells you to do that; it's a self-directed increase, scored down accordingly rather than assumed as the default. (Re-scored 5.0, down from 7.5, on re-audit Sep 3, 2026 — the prior score was written against an invented 'practitioner-prescribed 1-2 capsule range' that isn't on this label.)

60 capsules per bottle at ~$28 retail = $0.47 per cap. At the label's 1-capsule serving, that's $14/month; the 'priciest on the list' framing below assumes a self-directed 2-cap/day protocol ($28/month, 1000 mg total) — not the labeled dose. Either way, per active mg it's $0.47 ÷ 12.5 mg withanolides/cap = ~$0.038 per mg active withanolide, the highest per-active-mg cost on the list — premium for the QC pedigree, not for the active extract. Nutricost ($0.0078/mg) is ~4.8× cheaper per active mg for an arguably superior (patent-locked) extract. The cost premium is justified for the audiences that need practitioner-channel QC; it's NOT justified on a per-active-mg basis if QC clean-label isn't your specific need.